ABT - Abbott Laboratories
A diversified healthcare company spanning diagnostics, medical devices, nutrition, and established pharmaceuticals, with a strong presence in rapid testing and cardiac devices.
Finlify Score
29.8 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$105.61
-2.21%
52W Range
$81.97 - $137.49
Market Cap
$158.1B
-2.2%Compared to previous day
2026 Q1 Revenue
$11.2B
-2.6%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
35 analysts in latest ratings feed
RSI
69.2
40-70 moderate
2Y Range Position
40%
-25.2% from high / +28.8% from low
Beta
0.57
Relative to market benchmark
MACD
0.90
MACD line 3.87 / signal line 2.98
Fundamental Trend
Growth 9.7Financial Health
Quality 44.8Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID29.8 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $11.2B-2.6% | $11.5B+0.8% | $11.4B+2.0% | $11.1B+7.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.3B-40.2% | $2.3B+9.4% | $2.1B+0.2% | $2.1B+21.2% |
| Net Income | $1.1B-39.4% | $1.8B+8.0% | $1.6B-7.6% | $1.8B+34.3% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
The Finlify signal for ABT as of 2026-07-23 is AVOID, with a Finlify Score of 26.9 out of 100, which appears to be primarily driven by a very low Fundamental Trend score and weak Relative Strength.
Technical
The asset's Relative Strength score of 16.8/100 suggests a notable lack of momentum compared to its peers or the broader market. While recent short-term returns show an 11.3% gain over 20 days and 8.6% over 60 days, and the RSI(14) is at 64.2, the overall technical picture, as indicated by the low Relative Strength, may suggest underlying weakness. The Accumulation/Volume score is moderate at 52.2/100.
Fundamentals
A very low Fundamental Trend score of 9.7/100 appears to be a significant factor contributing to the overall signal, indicating potential challenges in the company's underlying financial performance. The Financial Quality score is 44.8/100, suggesting below-average financial health. With a P/E ratio of 27.8x and a P/S ratio of 4.1x, the valuation metrics may appear somewhat elevated, especially in light of the weak fundamental trend, despite a dividend yield of 2.50% and a low beta of 0.6.
Macro Context
The current macro environment, characterized by a 10Y Treasury Yield of 4.7% and a 2Y Treasury Yield of 4.3%, suggests a higher interest rate landscape, which could potentially influence valuation multiples for growth-oriented assets. Inflation metrics, with CPI YoY at 3.7% and Core PCE YoY at 3.4%, may indicate persistent cost pressures, although the asset's low beta of 0.6 might offer some defensive characteristics.
Key Risks
- The very low Fundamental Trend score of 9.7/100 suggests potential deterioration in the company's underlying financial performance.
- A Relative Strength score of 16.8/100 indicates that the asset may be underperforming its peers or the broader market.
- Valuation metrics such as a P/E of 27.8x and P/S of 4.1x appear somewhat elevated, particularly when combined with a weak fundamental trend.